Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 23:16:3171-3182.
doi: 10.2147/IDR.S408228. eCollection 2023.

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM

Junyang Kuai  1 , Yawei Zhang  1 , Binghuai Lu  2 , Hongbin Chen  1 , Yulin Zhang  2 , Henan Li  1 , Yuanyuan Wang  3 , Qi Wang  1 , Hui Wang  1 , Xiaojuan Wang  1
Affiliations

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM

Junyang Kuai et al. Infect Drug Resist. .

Abstract

Background: It is often challenging to select appropriate combination therapies to treat infections caused by carbapenem-resistant Enterobacterales (CRE) with high-level resistance to carbapenem.

Methods: We investigated the in vitro synergistic activity of ceftazidime-avibactam-, polymyxin- or tigecycline-, and meropenem-based combinations using checkerboard assays against 16 CRE including Klebsiella pneumoniae carrying blaKPC-2 (CR1-blaKPC-2) and Enterobacter cloacae carrying blaNDM-1 (CR2-blaNDM-1) with meropenem MICs ≥128 mg/L. Time-kill assays were used to observe synergistic bactericidal activity.

Results: Meropenem in combination with ertapenem, amikacin, tigecycline or polymyxin B, and tigecycline plus ceftazidime-avibactam showed weak synergistic activities against CR1-blaKPC-2 and CR2-blaNDM-1. Polymyxin B combined with tigecycline or ceftazidime-avibactam, and ceftazidime-avibactam plus amikacin showed synergistic effects against two tigecycline-non-susceptible KPC-producers or three ceftazidime-avibactam-resistant NDM-producer, and 50% (5/10) of strains with amikacin MICs ≥4096 mg/L, respectively. Synergistic interactions of ceftazidime-avibactam plus aztreonam or meropenem in checkerboard assays were measured for 100% (16/16) and 93.8% (15/16) of strains, respectively. The time-kill assay further verified that the ceftazidime-avibactam combination had the potential to restore aztreonam susceptibility and reduced meropenem MICs to 8 mg/L.

Conclusion: Ceftazidime-avibactam plus aztreonam or meropenem could be an effective strategy for treating CRE infections, particularly those with high-level resistance to carbapenems and/or ceftazidime-avibactam.

Keywords: aztreonam; ceftazidime-avibactam; checkerboard assays; meropenem; synergistic effect; time-kill assays.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Time-kill assays against CR1-blaKPC-2 and CR2-blaNDM-1 in incubation with ceftazidime-avibactam (CZA) alone and ceftazidime-avibactam (CZA) in combination with aztreonam (ATM) or meropenem (MEM). Curves represent average concentrations of duplicate experiments. (A) CZA in combination with ATM against CR1-blaKPC-2 via time-kill assays at the concentration of 1/128× MIC CZA plus 1/128× MIC ATM, 1/64× MIC CZA plus 1/64× MIC ATM and 1/32× MIC CZA plus 1/32× MIC ATM. (B) CZA in combination with ATM against CR2-blaNDM-1 via time-kill assays at the concentration of 1/128× MIC CZA plus 1/128× MIC ATM, 1/64× MIC CZA plus 1/64× MIC ATM and 1/32× MIC CZA plus 1/32× MIC ATM. (C) CZA in combination with MEM against CR1-blaKPC-2 via time-kill assays at the concentration of 1/128× MIC CZA plus 1/128× MIC MEM, 1/64× MIC CZA plus 1/64× MIC MEM, and 1/32× MIC CZA plus 1/32× MIC MEM. (D) CZA in combination with MEM against CR2-blaNDM-1 via time-kill assays at the concentration of 1/16× MIC CZA plus 1/16× MIC MEM, 1/8× MIC CZA plus 1/8× MIC MEM, and 1/4× MIC CZA plus 1/4× MIC MEM.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Palacios-Baena ZR, Giannella M, Manissero D, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect. 2021;27(2):228–235. doi:10.1016/j.cmi.2020.10.016 - DOI - PubMed
    1. Wang Q, Wang X, Wang J, et al. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012-2016). Clin Infect Dis. 2018;67(suppl_2):S196–S205. - PubMed
    1. Stojowska-Swędrzyńska K, Łupkowska A, Kuczyńska-Wiśnik D, et al. Antibiotic heteroresistance in Klebsiella pneumoniae. Int J Mol Sci. 2021;23(1): 449. - PMC - PubMed
    1. Lu J, Qing Y, Dong N, et al. Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria. Saudi Pharm J. 2022;30(6):849–855. - PMC - PubMed
    1. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079–17. - PMC - PubMed